Average Co-Inventor Count = 6.07
ph-index = 9
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Boehringer Ingelheim International Gmbh (44 from 1,537 patents)
2. Centrexion Therapeutics Corporation (9 from 36 patents)
3. Smithkline Beecham Corporation (5 from 2,198 patents)
4. Convergence Pharmaceuticals Limited (3 from 24 patents)
5. Glaxo Group Limited (1 from 1,168 patents)
6. Smithkline Beecham Croporation (1 from 1 patent)
7. Glaxosmithkline LLC (356 patents)
8. Nerre Therapeutics Limited (9 patents)
63 patents:
1. 12209094 - CCR2 receptor antagonists and uses thereof
2. 11731981 - CCR2 receptor antagonists and uses thereof
3. 11691977 - Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide
4. 11376258 - Purine derivatives and the use thereof as medicament
5. 11166958 - 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
6. 11155539 - 4-pyridinylmethyl-morpholine derivatives and the use thereof as medicament
7. 11104670 - 4-pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament
8. 11046706 - CCR2 receptor antagonists and uses thereof
9. 10919898 - Medical use of compound III
10. 10875867 - Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide
11. 10849907 - Imidazopyridine derivatives and the use thereof as medicament
12. 10675268 - Somatostatin receptor subtype 4 (SSTR4) agonists
13. 10640486 - Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
14. 10577336 - Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists
15. 10479794 - Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide